OverviewSuggest Edit

Champions Oncology develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides Personalized Oncology Solutions that assist physicians in developing personalized treatment options for cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services.

TypePublic
Founded2007
HQHackensack, NJ, US
Websitechampionsoncology.com
Employee Ratings2.8
Overall CultureA-

Latest Updates

Employees (est.) (Jul 2019)115(+25%)
Job Openings20
Revenue (FY, 2020)$32.1 M(+19%)
Share Price (Jun 2021)$9.6(-2%)
Cybersecurity ratingBMore

Key People/Management at Champions Oncology

Ronnie Morris

Ronnie Morris

Chief Executive Officer and Director
Philip Breitfeld

Philip Breitfeld

Chief Strategy & Innovation Officer
David Miller

David Miller

Chief Financial Officer
Michael Ritchie

Michael Ritchie

Chief Commercial Officer
Karin Abarca Heidemann

Karin Abarca Heidemann

Vice President of Scientific Operations
Maria Mancini

Maria Mancini

Vice President of Pharmacology
Show more

Champions Oncology Office Locations

Champions Oncology has offices in Hackensack, Rockville and London
Hackensack, NJ, US (HQ)
1 University Plaza Dr #307
Rockville, MD, US
1330 Piccard Dr #025
London, GB
2 Royal College St
Show all (3)

Champions Oncology Financials and Metrics

Champions Oncology Revenue

Champions Oncology's revenue was reported to be $32.12 m in FY, 2020
USD

Revenue (Q3, 2021)

10.8m

Gross profit (Q3, 2021)

6.0m

Gross profit margin (Q3, 2021), %

55.2%

Net income (Q3, 2021)

740.0k

EBIT (Q3, 2021)

763.0k

Market capitalization (4-Jun-2021)

129.2m

Closing stock price (4-Jun-2021)

9.6

Cash (31-Jan-2021)

7.4m

EV

128.2m
Champions Oncology's current market capitalization is $129.2 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

7.1m8.3m11.6m8.9m11.2m15.4m20.2m27.1m32.1m

Revenue growth, %

(23%)26%

Sales and marketing expense

2.9m2.7m3.2m4.3m3.4m3.3m2.6m3.1m4.2m

General and administrative expense

5.5m4.6m6.1m5.3m5.2m5.0m4.1m4.7m6.6m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

1.6m1.7m2.4m2.1m1.5m2.9m3.0m2.4m3.7m1.9m1.9m1.8m2.8m3.0m2.6m3.7m4.5m3.6m5.0m5.2m5.1m6.2m6.7m6.4m6.7m7.6m9.0m9.5m10.1m10.8m

Cost of goods sold

3.1m3.5m3.4m3.8m3.9m4.3m5.3m5.6m4.8m

Gross profit

3.1m3.2m3.0m3.0m3.7m4.7m4.2m4.5m6.0m

Gross profit Margin, %

50%48%47%44%49%52%44%44%55%
USDQ1, 2012

Financial Leverage

-11.9 x
Show all financial metrics

Champions Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Champions Oncology Online and Social Media Presence

Embed Graph

Champions Oncology Company Culture

  • Overall Culture

    A-

    86/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Champions Oncology News and Updates

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018

HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and...

Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first...

Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York

HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at...

Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

HACKENSACK, N.J., July 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter...

Champions Oncology Blogs

A Needle in a Haystack – Finding Rare AML Cell Populations by Flow Cytometry

Hematologic malignancies include a wide array of lymphomas and leukemias that affect different immune cell subsets. Acute myelogenous leukemia (AML) is one of the most commonly occurring leukemias in adults and children. AML is a highly heterogenous disease that can be caused by spontane…

Stem Cell Transplantation in CLL: Almost Gone but Not Forgotten

Advances in molecular diagnostics and ex vivo drug sensitivity screening have greatly improved the use of targeted therapies for the treatment of chronic lymphocytic leukemia (CLL), such as B cell receptor signaling inhibitors, which include the Bruton tyrosine kinase (BTK) inhibitors li…

Insights and Advances in Bladder Cancer

Bladder cancer is a relatively common form of cancer that is defined as either pre-invasive or invasive, and non-muscle invasive bladder cancer (NMIBC) is the most-commonly diagnosed subtype[1]. NMIBC is typically treated by surgical resection and/or intravesical delivery of chemo- or im…

Current Trends in Glioblastoma Therapies

Glioblastoma multiforme (GBM) is an aggressive form of primary malignancy of the central nervous system (CNS) that causes brain tumors. GBM has been associated with poor prognoses and high mortality rates and a 5-year relative survival rate ranging from 6-22% percent depending on age of …

What’s behind the mask? Lumin Bioinformatics – using Champions’ powerful data visualization and analytic software to drive target discovery

Answers provided by Alexis Santana, PhD – Manager, Business Development at Champions Oncology

Culture Clash: Autologous versus Allogeneic Cells in Oncology

Adoptive cell therapies (ACTs) are being broadly tested and implemented in the treatment of a wide range of cancers, but the success of these therapies has been limited by the challenges of expanding cells of interest ex vivo. Most studies collect peripheral blood cells from a patient an…
Show more

Champions Oncology Frequently Asked Questions

  • When was Champions Oncology founded?

    Champions Oncology was founded in 2007.

  • Who are Champions Oncology key executives?

    Champions Oncology's key executives are Ronnie Morris, Philip Breitfeld and David Miller.

  • How many employees does Champions Oncology have?

    Champions Oncology has 115 employees.

  • What is Champions Oncology revenue?

    Latest Champions Oncology annual revenue is $32.1 m.

  • What is Champions Oncology revenue per employee?

    Latest Champions Oncology revenue per employee is $279.3 k.

  • Who are Champions Oncology competitors?

    Competitors of Champions Oncology include Pyramid Biosciences, Gene Techno Science and Rgenta.

  • Where is Champions Oncology headquarters?

    Champions Oncology headquarters is located at 1 University Plaza Dr #307, Hackensack.

  • Where are Champions Oncology offices?

    Champions Oncology has offices in Hackensack, Rockville and London.

  • How many offices does Champions Oncology have?

    Champions Oncology has 3 offices.